Anemia in heart failure: clinical and pathogenetic relationship and treatment methods
https://doi.org/10.15829/1728-8800-2025-4495
EDN: UKIUGJ
Abstract
Noncommunicable diseases are called the epidemic of the 21st century. Heart failure (HF) is one of them. Among the diseases concomitant to HF, anemia is one of the most common. It is known that HF and anemia as separate conditions can be treated at the outpatient stage. However, their combination is a serious problem. The review presents current view on anemia etiology in HF, their pathogenetic relationship, clinical associations and prognostic significance of anemia in HF, as well as methods for treating anemia against the background of HF and some features that should be taken into account during HF treatment in patients with anemia.
About the Authors
D. Yu. Gamayunov
Irkutsk State Medical University;
Irkutsk City Clinical Hospital № 1
Russian Federation
Russian Federation
Irkutsk
A. N. Kalyagin
Irkutsk State Medical University;
Irkutsk City Clinical Hospital № 1
Russian Federation
Russian Federation
Irkutsk
A. A. Aknazarova
Irkutsk State Medical University
Russian Federation
Russian Federation
Irkutsk
T. M. Maksikova
Irkutsk State Medical University;
OOO Medical Clinic Atlant
Russian Federation
Russian Federation
Irkutsk
D. O. Kiselev
Irkutsk State Medical University
Russian Federation
Russian Federation
Irkutsk
E. S. Chuiko
Irkutsk City Clinical Hospital № 1
Russian Federation
Russian Federation
Irkutsk
References
1. Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342-56. doi:10.1002/ejhf.1858.
2. Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.) doi:10.15829/1560-4071-2024-6162.
3. Shepel RN, Drapkina OM, Kontsevaya AV, et al. Ambulatory care sensitive diseases/conditions in adult patients. A systematic review. Cardiovascular Therapy and Prevention. 2024;23(9):4128. (In Russ.) doi:10.15829/1728-8800-2024-4128.
4. Tkachenko EI, Borovkova NYu, Buyanova MV. Anemia in patients with chronic heart failure: a view of pathogenesis and treatment options. Doctor.Ru. 2019;2(157):31-6. (In Russ.) doi:10.31550/1727-2378-2019-157-2-31-36.
5. Rajesh R, Gaskina AA, Villevalde SV, et al. Clinical associations of anemia in patients with chronic heart failure. Clinical pharmacology and therapy. 2018;27(4):12-6. (In Russ.)
6. Gurkina AA, Stuklov NI, Kislyi ND, et al. Characteristics of anemia in heart failure: iron metabolism, erythropoietic activity and markers of inflammation. Cardiovascular Therapy and Prevention. 2023;22(1):3332. (In Russ.) doi:10.15829/1728-8800-2023-3332.
7. Menshikova LV, Babanskaya EB. Risk factors of progression of chronic heart failure. Sibirskij medicinskij zurnal (Irkutsk). 2015;136(5):69-73. (In Russ.)
8. Gorokhovskaya GN, Martynov AI, Yun BL, et al. The modern view of general practitioner on the problem of iron deficiency anemia in patients with cardiovascular pathology. Medical Council. 2020;(14):70-8. (In Russ.) doi:10.21518/2079-701X-2020-14-70-78.
9. Khanyukov AA, Pesotskaya LA, Sapozhnichenko LV, et al. The prevalence and pathogenesis of anemia in patients with chronic heart failure. Hematology. Transfusiology. Eastern Europe. 2021; 7(2):219-28. (In Russ.) doi:10.34883/PI.2021.7.2.010.
10. Małyszko J, Tomaszuk-Kazberuk A, Dobrzycki K, et al. Vitamin D deficiency and anemia is highly prevalent and dependent on the etiology of heart failure: A pilot study. Cardiol J. 2021;28(2):262- 70. doi:10.5603/CJ.a2019.0003.
11. Pan J, Liu M, Huang J, et al. Impact of anemia on clinical outcomes in patients with acute heart failure: A systematic review and meta-analysis. Clin Cardiol. 2024;47(2):e24228. doi:10.1002/clc.24228.
12. Buliga-Finis ON, Ouatu A, Tanase DM, et al. Managing anemia: point of convergence for heart failure and chronic kidney disease? Life (Basel). 2023;13(6):1311. doi:10.3390/life13061311.
13. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018; 138(1):80-98. doi:10.1161/CIRCULATIONAHA.118.030099.
14. Murkamilov IT, Kaliev RR, Sarybaev Ash, et al. Chronic renocardial continuum in glomerulonephritis. Kardiologiia. 2016; 56(9):55-9. (In Russ.) doi:10.18565/cardio.2016.9.55-59.
15. Vatutin NT, Taradin GG, Kanishcheva IV, et al. Anaemia and iron deficiency in chronic heart failure patients. Kardiologiia. 2019;59(4S):4-20. (In Russ.) doi:10.18087/cardio.2638.
16. Kuriyama S, Maruyama Y, Honda H. A new insight into the treatment of renal anemia with HIF stabilizer. Ren. Replace Therapy. 2020;6:63. doi:10.1186/s41100-020-00311-x.
17. Shchukina EV, Malovichko IS, Alyoshechkin PA, et al. Assessment of quality of life in patients ischemic heart failure with anemia. Problemy jekologicheskoj i medicinskoj genetiki i klinicheskoj immunologii. 2021;6(168):225-32. (In Russ.)
18. Goryaev YuA, Kalyagin AN. Role of anemia in deterioration of the forecast and decompensation of chronic heart failure in patients with rheumatic heart diseases. Sibirskij medicinskij zurnal (Irkutsk). 2006;67(9):63-5. (In Russ.)
19. Loncar G, Obradovic D, Thiele H, et al. Iron deficiency in heart failure. ESC Heart Fail. 2021;8(4):2368-79. doi:10.1002/ehf2.13265.
20. Kulikov IA, Demikhov VG. Prevalence of anaemia and predictors of its development in elderly and senile patients. Journal of New Medical Technologies. eEdition. 2024;18(4):42-6. (In Russ.) doi:10.24412/2075-4094-2024-4-1-6.
21. Mendoza-Beltrán F, Echeverría LE, Rivera-Toquica A, et al. Prognostic value of the diagnosis of anemia in patients with heart failure: an analysis based on the Colombian heart failure registry (RECOLFACA). BMC Cardiovasc Disord. 2024;24(1):648. doi:10.1186/s12872-024-04291-2.
22. Yarmedova SF, Yavelov IS, Drapkina OM. Causes of shortness of breath in patients with stable coronary heart disease. Cardiovascular Therapy and Prevention. 2022;21(9):3334. (In Russ.) doi:10.15829/1728-8800-2022-3334.
23. Askarov AR, Vertkin AL, Rudnitskaya MA, et al. Peculiarities of COVID-19 infection among hospitalized patients in the city hospital of Moscow during the 6th wave of the pandemic. Lechaschi vrach. 2023;26(7-8):93-8. (In Russ.) doi:10.51793/OS.2023.26.8.014.
24. Lutai YuA, Kryuchkova ON, Itskova EA, et al. Chronic heart failure among elderly age people: special diagnostics and treatment. Crimean Journal of Internal Diseases. 2020;2:37-43. (In Russ.)
25. Gadó K, Khodier M, Virág A, et al. Anemia of geriatric patients. Physiol Int. 2022;109(2):119-34. doi:10.1556/2060.2022.00218.
26. Kurz K, Lanser L, Seifert M, et al. Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure. ESC Heart Fail. 2020;7(4):1880-90. doi:10.1002/ehf2.12755.
27. Campodonico J, Nicoli F, Motta I, et al. Prognostic role of transferrin saturation in heart failure patients. Eur J Prev Cardiol. 2021;28(15):1639-46. doi:10.1093/eurjpc/zwaa112.
28. Varsanova EA, Egorova AYu, Fedorenko AR. Iron deficiency anemia and chronic heart failure. Smolenskij medicinskij al'manah. 2023;2:54-8. (In Russ.) doi:10.37903/SMA.2023.2.16.
29. Gurkina AA, Stuklov NI, Kislyi ND, et al. New possibilities of pathogenetic correction of anemia in chronic heart failure. Clinical Medicine (Russian Journal). 2023;101(7-8):387-94. (In Russ.) doi:10.30629/0023-2149-2023-101-7-8-387-394.
30. Bagri AE, Shchukina EV, Orekhova VG, et al. Correction of iron deficiency anemia in patients with ischemic heart failure. Problemy jekologicheskoj i medicinskoj genetiki i klinicheskoj immunologii. 2022;1(169):1-17. (In Russ.)
31. Rocha BML, Cunha GJL, Menezes Falcão LF. The burden of iron deficiency in heart failure: therapeutic approach. J Am Coll Cardiol. 2018;71(7):782-93. doi:10.1016/j.jacc.2017.12.027.
32. Singer CE, Vasile CM, Popescu M, et al. Role of iron defificiency in heart failure — clinical and treatment approach: an overview. Diagnostics. 2023;13:304. doi:10.3390/diagnostics13020304.
33. Kazantseva TA, Rajesh R, Efremovtseva MA, et al. Anemia and chronic heart failure. Cardiovascular Therapy and Prevention. 2010;9(4):116-23. (In Russ.)
34. Haase VH. HIF-PH inhibitors for anemia of CKD. Kidney Int. Suppl. 2021;11:8-25. doi:10.1016/j.kisu.2020.12.002.
35. Nakamura M, Imamura T, Sobajima M, et al. Initial experience of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with heart failure and renal anemia. Heart Vessels. 2023;38(2):284-90. doi:10.1007/s00380-022-02181-1.
36. Imamura T, Hori M, Tanaka S, et al. Impact of hypoxia-inducible factor prolyl hydroxylase inhibitor on heart failure with preserved ejection fraction. Medicina (Kaunas). 2021;57(12):1319. doi:10.3390/medicina57121319.
37. Orlova NV, Karseladze ND. Anemia of chronic diseases. Medical Alphabet. 2024;(13):14-20. (In Russ.) doi:10.33667/2078-5631-2024-13-14-20.
38. Weir MR. Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. Am.J. Nephrol. 2021;52:450-66. doi:10.1159/000516901.
39. Curtain JP, Adamson C, Docherty KF, et al. Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/ valsartan. JACC Heart Fail. 2023;11(7):749-59. doi:10.1016/j.jchf.2022.12.012.
Supplementary files
Review
For citations:
Gamayunov D.Yu., Kalyagin A.N., Aknazarova A.A., Maksikova T.M., Kiselev D.O., Chuiko E.S. Anemia in heart failure: clinical and pathogenetic relationship and treatment methods. Cardiovascular Therapy and Prevention. 2025;24(8):4495. (In Russ.) https://doi.org/10.15829/1728-8800-2025-4495. EDN: UKIUGJ
Views:
87
Email this article 
